Fixed-term

Research background The main research interest of our group lies in the reaction of metabolic tissues to various environmental factors, such as temperature challenges and food constituents. We recently identified the Aryl Hydrocarbon Receptor Repressor (AhRR) as a pivotal regulator of thermogenesis and metabolic processes (Graelmann, FJ et al, Mol Metab 2024). In this project, the candidate will investigate how environmental factors influence the plasticity of thermogenic adipose tissues, including pathways controlling preadipocytes and endothelial cells (Reverte-Salisa, L et al, Nat Cell Biol 2024). To investigate these processes the candidate will use mouse models, classical in vitro methods but also cutting-edge technologies, such as flow cytometry, metabolomics, and snRNA sequencing.  The position is available within the Transregional Collaborative Research Centre (TRR) 333 “BATenergy: Brown and Beige Fat – Organ Crosstalk, Signaling and Energetics” funded by the Deutsche Forschungsgemeinschaft (DFG). For further information please refer to https://www.limes-institut-bonn.de/en/research/research-departments/unit-2/foerster-lab/foerster-lab-home/ and https://www.trr333.uni-bonn.de/  We offer opportunity to conduct your PhD thesis A thriving academic environment A professional career development program Participation in the university-wide pension system (VBL) Access to extensive university sports program A salary based on the TV-L scale (E13, 65%)  Your profile Applicants should hold a master degree in molecular biology, pharmacy, immunology, or similar topics. Candidates with experience in molecular cell biology, pharmacology or biochemistry are encouraged to apply. Methodological experience in cell signaling, multicolor flow cytometry, transcriptomics and bioinformatics is advantageous. Good communication skills and fluency in English are essential. We expect a highly motivated candidate with willingness to work in a diverse team.  Diversity and equal opportunity The University of Bonn promotes an open, respectful, and non-discriminatory academic culture and is actively committed to equal opportunity and family friendliness. We aim to eliminate structural disadvantages and to strengthen diversity in research, teaching, and administration. Therefore, we welcome all applications, regardless of ethnic or social background, gender, sexual orientation, religion or belief, disability, or age.  Applications from women and people with a documented severe disability (or equivalent status) will be given preferential consideration in accordance with the State Equality Act (LGG) NRW and Social Code (SGB) IX.  Contact Dr. Laia Rexerte Salisa E-Mail: laia@uni-bonn.de 

About the Role The Research Fellow at the Department of Biosciences will support the delivery of the MRC-funded project focused on developing and evaluating microRNA-based nanoscale delivery systems for inflammatory bowel disorders. The Research Fellow will bring strong research capability and will have specific responsibility for planning, conducting, and writing up research Duties & Research Responsibilities of the role: • Manage, plan and conduct own research activity using recognised approaches, methodologies, and techniques within the research area. • Contribute to the undertaking of general laboratory duties such as ordering consumables/chemicals, maintenance of key laboratory equipment, where appropriate. • Resolve problems, in meeting research objectives and deadlines in collaboration with others. • Identify opportunities and assist in writing bids for research grant applications. Prepare proposals and applications to both external and/or internal bodies for funding, contractual or accreditation purposes. • Write up research work for publication and/or contribute to the dissemination at national/international conferences, resulting in successful research outputs. • Build relationships with both internal and external collaborators to exchange information, develop collaborative projects and identify potential opportunities for future collaboration • Maintain awareness of IP opportunities and help prepare patent documents. • Collaborate with academic colleagues on areas of shared interest for example, course development, collaborative or joint research projects. • Contribute to teaching that is in balance with wider contributions to research and other activities. • Guide and mentor PhD and Graduate student members within the research group. Our current research portfolio has a particularly strong record in the application of novel technologies across interdisciplinary domains. Experience in metabolomics, microbiology, cell culture, organoid and organ-on-chip technologies is therefore essential or highly desirable for this role. For more details, please take a look at the role profile. We’ll still consider applications even if you don’t meet every single one of the requirements, so don’t be put off if you don’t match them perfectly. Interviews W/C 13th July 2026 Start date – 1st September 2026 Join Us 30 – 35 days annual leave per year plus statutory bank holidays and 5 university closure days pro rata. Salary Sacrifice Retirement Savings Plan with life assurance and income protection. Available to colleagues who choose to opt out of the contractual pension scheme. Minimum colleague contributions of 0% matched with minimum NTU contributions of 8%. Access to a wealth of formal and informal professional development opportunities to develop your skills and advance your career. Range of health and wellbeing services, including a Health Cash Plan, voluntary benefits, discounts, and savings for all colleagues. And a whole lot more…Find out more about the range of benefits we offer. Come and be part of our success. Apply today. About Us The School of Science and Technology at Nottingham Trent University (NTU) is an exciting multidisciplinary environment for learning, teaching and research, with some of the best facilities in the UK. We pride ourselves on delivering high-quality teaching and diverse, real-world research. We specialise in biosciences, chemistry, computing and technology, as well as engineering, forensic science, mathematics, physics and sport science. This mix of traditional and modern subjects encourages and inspires future innovators. Our courses in the Department of Biosciences are research-led, providing students with cutting-edge knowledge and access to high-specification facilities. It is one of the many reasons why our courses are accredited by the Institute of Biomedical Science, the Royal Society of Biology and the Chartered Institute of Ecology and Environment Management. For any informal queries about the role or the team, please contact Dr Christos Polytarchou (Associate Professor in Health and Disease) at christos.polytarchou@ntu.ac.uk. Safe and Inclusive At NTU, we continue to build an inclusive culture that encourages, supports and celebrates the diverse voices and experiences of our students and colleagues. By championing positive wellbeing, we promote an environment where all can thrive and reach their full potential. We welcome the unique contributions that you can bring and we encourage people from underrepresented communities and backgrounds to apply to join our team. Please note that unfortunately, this role has been assessed as ineligible for sponsorship under the UK Visas & Immigration points-based immigration system however, we recommend that you assess your eligibility before applying for this position. For more information visit the Government Skilled Worker visa support page. However, applications are welcome from candidates who do not currently have the right to work in the UK, but who would be eligible to obtain a valid visa via another route. Please consult the Home Office website for further information. Please note that this role is covered by the Rehabilitation of Offenders Act (1974) and successful applicants will be asked to declare any unspent criminal convictions. Supporting Documents JD 552318 – Research Fellow (PDF, KB) Apply Now

The MRC PPU is one of the world’s most renowned centres for research on protein phosphorylation and ubiquitylation (http://www.ppu.mrc.ac.uk/). Many world-leading researchers in the field of signal transduction have trained within the MRC PPU. The major aims of the MRC PPU are to advance understanding of the role of protein phosphorylation and ubiquitylation in cell regulation and human disease, to facilitate the development of drugs to treat diseases caused by abnormalities in phosphorylation, to generate reagents and improve technologies. A key remit of the MRC PPU is to train the next generation of scientists who will advance our understanding in this crucial area of medical research. Faculty of Life Sciences (FLS): The MRC PPU is based within the Faculty of Life Sciences at the University of Dundee, a world-class academic institution with a reputation for the excellence of its research, its high-quality teaching and student experience, and the strong impact of its activities outside academia. With 900 staff from over 60 countries worldwide the Faculty provides a dynamic, multi-national, collegiate and diverse environment with state-of-the-art laboratory, technology and teaching facilities. Division of Signal Transduction Unit (DSTT): The Division of Signal Transduction Therapy (DSTT) was established in 1998. This division operates as a unique collaboration between scientists in the MRC PPU and signalling researchers at the University of Dundee’s Faculty of Life Sciences and the pharmaceutical industry. The DSTT is widely regarded as a model for how academia should interact with industry. The DSTT operates as a simple bridging mechanism to enable our PIs working on ubiquitylation and phosphorylation to effectively interact with major pharmaceutical companies to help accelerate the early stages of drug discovery. We are recruiting exceptional individuals to join as Postdoctoral Researchers in the laboratories of Prof Miratul Muqit and Prof Ian Ganley. This is a fixed-term appointment for 36 months. We are recruiting up to four postdoctoral scientists to join anexciting new collaborative project fundedby the Aligning Science Across Parkinson’s (ASAP) network (https://parkinsonsroadmap.org/news/261m-investment-toward-personalized-treatments/) with expertise in signalling, cell biology, mouse neurobiology, CRISPR gene-editing or proteomics to investigate the role of mitochondrial mechanisms underlying Parkinson’s disease. The project will be based in the Muqit Lab or the Ganley Lab at the University of Dundee and seeks to understand the molecular and mitochondrial basis of the neurodegenerative disorder, Parkinson’s disease (PD), through open and interdisciplinary collaborations with leading research groups based at Harvard Medical School, UCLA and Gottingen University. The successful applicant(s) will undertake discovery-driven research projects as part of a the ASAP award with principles in open science and resource sharing that will ultimately lead to better understanding of PD and how to diagnose and treat it. The project(s) will investigate the role of mitochondria in Parkinson’s disease. Previous research by the Muqit and Ganley labs has contributed to the development of targeted therapies for PINK1-induced mitophagy, which entered clinical trials for PD patients last year. However, recent advances have highlighted additional cellular pathways including proteostatic stress as modulators of mitophagy. The projects will be aimed at uncovering entirely new understanding of mitochondrial stress that may lead to new concepts for therapeutic exploitation in PD. The successful candidate(s) will benefit from an interdisciplinary environment in both the Ganley and Muqit Labs in the MRC PPU in Dundee. The Muqit laboratory forms part of the national UK DRI and the EMBO YIP networks and successful applicants will have access to UK DRI and EMBO sponsored opportunities for training and self-development. The MRC unit also collaborates with a major pharmaceutical company that support the Division of Signal Transduction Therapy, which provides opportunities for interaction with industry and potential exploitation of new discoveries made in the labs. Both Lab actively participates in Public Engagement, and successful candidates will be encouraged to be involved in public and patient involvement. ASAP places high value in training the next generation of researchers and successful candidates will benefit from attending many ASAP scientific and networking events during their research. In addition, the ASAP initiative also provides to those that are eligible a family care stipend – up to $10,000 USD supplement on top of salary which can be applied for following appointment. Overall, this position provides an exciting opportunity to be involved in world-class research projects and for the successful applicant to carve themselves a major international reputation. The successful candidate(s) will have an opportunity to be trained in a suite of state-of-the-art techniques during the project Relevant publications: Singh, P.K., Agarwal, S., Volpi, I., Wilhelm, L.P., Becchi, G., Keenlyside, A., Macartney, T., Toth, R., Rousseau, A., Masson, G.R., Ganley, I.G., Muqit, M.M. (2025) Kinome screening identifies integrated stress response kinase EIF2AK1 / HRI as a negative regulator of PINK1 mitophagy signalling. Science Adv 11: eadn2528. Bagnoli, E., Lin Y-E., Burel, S., Jaimon, E., Antico, O., Themistokleous C., Nikoloff, J.M., Morella, I., Watzlawik J.O., Fiesel, F.C., Springer, W., Tonelli, F., Brooks, S.P., Sunnett, S.B., Brambilla, R., Alessi, D.R., Pfeffer, S.R., Muqit, M.M. (2025) Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain. Proc Natl Acad Sci USA 122: e2412029122. Antico, O., Thompson, P.W., Hertz, N.T., Muqit, M.M., Parton, L.E. (2025) Targeting mitophagy in neurodegenerative diseases. Nature Rev Drug Discov 24: 276-299. Raimi, O.G., Ojha, H., Ehses, K., Dederer, V., Lange, S.M., Rivera, C.P., Deegan, T.D., Chen, Y., Wightman, M., Toth, R., Labib, K.P.M., Mathea, S., Ranson, N., Fernandez-Busnadiego, R., Muqit, M.M. (2024) Mechanism of human PINK1 activation at the TOM complex in a reconstituted system. Science Adv 10: eadn7191. Lenka, D.R., Dahe, S.V., Antico, O., Sahoo, P., Prescott, A.R., Muqit, M.M., Kumar, A. (2024) Additional feedforward mechanism of Parkin activation via binding of phospho-UBL and RING0 in trans. eLife 13: RP96699 doi: 10.7554/eLife.96699 Lorentzen, K.C., Prescott, A.R., Ganley, I.G. (2025) Artificial targeting of autophagy components to mitochondria reveals both conventional and unconventional mitophagy pathways. Autophagy 21: doi: 10.1080/15548627.2024.2395149. Longo, M., Bishnu, A., Risiglione, P., Montava-Garriga, L., Cuenco, J., Sakamoto, K., MacKintosh, C., Ganley, I.G. (2024) Opposing roles for AMPK in regulating distinct mitophagy pathways. Mol Cell 84: doi: 10.1016/j.molcel.2024.10.025. Your priorities will include: Molecular based mechanistic research studies Design and performing kinome-wide CRSIPR/Cas9 knock-down screen and sgRNA enrichment analysis. Proteomic discovery platforms including PTM proteomics and organellar isolation workflows Public and patient involvement and engagement presentations. Dissemination of protocols and data openly and through formal peer-reviewed publications. Advising and mentoring undergraduate and PhD students. Candidate requirements: Have a PhD in Cell Biology, Biochemistry, Proteomics, Mouse Neuroscience, or related discipline with outstanding academic track record and a publication record in internationally recognised peer-reviewed journals. Have a strong interest in signal transduction research and how disruptions of these pathways are linked to human disease. Have a strong background in mouse neurobiology, biochemistry, cell biology proteomics

Details Funded by Tenovus Scotland (Grampian, Highlands & Islands), this project covers Home/UK tuition fees and essential research costs.  The MSc by Research programme at the University of Aberdeen is for students interested in a research-intensive master’s degree. It is designed specifically to enhance your skills for a PhD or research career. You can find further information about our academic requirements and MSc by Research programme structure here. Patients with cancer are at increased risk of developing life-threatening blood clots such as those that form in the deep veins and can break off and block the lungs (pulmonary embolism) or those that form in arteries and can cause heart attacks and strokes. Cancer associated blood clots increases the risk of death approximately 3-fold compared to cancer patients without a clot. In addition, non-fatal blood clots can greatly impact patient quality of life. Cancer cells can release factors that initiate the clotting process and activate tiny blood cells called ‘platelets’ that form the initial plug of a blood clot. Whether a clot persists and causes a blockage of a blood vessel depends on both the clot formation and break down process. Clot breakdown is regulated by both activators and inhibitors of the process. The clot breakdown process is normally tightly regulated but when there is an imbalance, this can lead to the development of life-threatening blood clots. These regulators of the clot formation and breakdown process can be released by platelets and the cells that line the inside of blood vessels as well as from cancer cells. This project aims to mimic the inflammatory environment of a 3D breast cancer tumour in a dish. This will allow us to establish how these tumours affect platelets and the cells lining the blood vessel wall and the impact of this on clot formation and breakdown. The different cell types will be incubated together and changes in levels and releases of these regulators will be measured and the effect they have on clot formation and breakdown will be investigated. Currently, prevention and treatment of blood clots is with use of anticoagulant drugs to reduce clot formation. However, these drugs do not remove the existing clot and it is clear that the clinical significance is determined by the combined effects of clot formation and clot breakdown. Therefore, understanding the mechanisms that contribute to the development of blood clots and exploring strategies that enhance clot breakdown in cancer patients could lead to improved and more targeted therapeutic options that enhance survival. We will model a proinflammatory tumour microenvironment using breast cancer cell monolayers or 3D mammospheres stimulated with proinflammatory cytokines. Co-culture models will be utilised to determine the impact on gene expression and protein release, exposure and activity in endothelial cells and platelets. The successful candidate will gain experience in cell culture, platelet isolation, haemostatic assays qPCR, Western blotting and fluorescence microscopy.  Informal enquiries are encouraged and can be directed to Dr Claire Whyte (c.s.whyte@abdn.ac.uk).  Candidate Background: It would be an advantage to have cell culture experience but training will be provided. We actively encourage applications from diverse career paths and backgrounds and across all sections of the community, regardless of age, disability, ethnicity, gender, gender expression, sexual orientation and transgender status, amongst other protected characteristics. We also invite applications from those returning from a career break, industry or other roles. We typically require a minimum of a 2:1 UK Honours degree (or equivalent), but exceptions can be made where applicants can demonstrate excellence in alternative ways, including, but not limited to, performance in masters courses, professional placements, internships or employment. Application Procedure To apply, please submit the following documents via email to smmsn-pgrenquiries@abdn.ac.uk A cover letter addressed to the supervisor of the project you’re applying for. An up-to-date CV detailing your academic qualifications, employment history, and any other relevant experience. Please ensure your current permanent address is clearly stated, as this will be used to determine your fee status. Clear copies of your degree certificates and transcripts (if available). Evidence of settled or pre-settled status (if applicable). Please send your application with documents attached as a single email with the subject line: “Tenovus_CW – [Your Name]” The deadline for applications is 23:59 GMT on the 8th July 2026. Please note that incomplete applications will not be considered. For any enquiries regarding your application or the application process, please contact smmsn-pgrenquiries@abdn.ac.uk Funding Notes This MSc by Research project is funded by Tenovus Scotland (Grampian, Highlands & Islands). The funding package is limited to tuition fees at the Home/UK rate and research costs. The anticipated start date for the project is October 2026; it does not provide a student stipend. The project is expected to commence in October 2026. References 1.Fahad S Alshehri, Abdurahman Alloghbi, Abdulrahman Alshalani, Hassan Abu Sabah, Claire S Whyte. Cancer-associated Thrombosis (CAT); mechanisms and treatment options. Thrombosis Journal. 2025; 23 (1) 116.2. Sabrkhany S, Kuijpers MJE, Oude Egbrink MGA, Griffioen AW. Platelets as messengers of early-stage cancer. Cancer Metastasis Rev. 2021;40(2):563-573.3. Dhami SPS, Patmore S, Comerford C, et al. Breast cancer cells mediate endothelial cell activation, promoting von Willebrand factor release, tumor adhesion, and transendothelial migration. J Thromb Haemost. 2022;20(10):2350-2365.4. Tinholt M, Tekpli X, Torland LA, et al. The breast cancer coagulome in the tumor microenvironment and its role in prognosis and treatment response to chemotherapy. J Thromb Haemost. 2024;22(5):1319-1335.ent response to chemotherapy. J Thromb Haemost. 2024;22(5):1319-1335.

Details This fully-funded PhD studentship, supported by Medical Research Scotland (MRS), will be delivered jointly by the University of Aberdeen and Vesiculab Ltd. The studentship provides the first-class academic and industry training needed to equip the successful candidate for a scientific career in an increasingly competitive market. Supervisory Team Dr Nimesh Mody: School of Medicine, Medical Sciences & Nutrition, University of Aberdeen Professor Mirela Delibegovic: School of Medicine, Medical Sciences & Nutrition, University of Aberdeen Dr Naveed Akbar: Radcliffe Department of Medicine, University of Oxford Dr Dimitri Aubert: Vesiculab Ltd. Project Description Atherosclerosis, the buildup of fatty deposits in blood vessels, is a major cause of heart attacks and strokes. Recent research shows that tiny particles called extracellular vesicles (EVs), released by unhealthy cells, can carry harmful molecules that worsen this disease. These EVs are produced when lipotoxic pathways increase in the liver, especially in response to unhealthy diets or inflammation. This leads to higher levels of lipotoxicity and insulin resistance linked to both liver and heart disease. Our previous work and other studies have shown that blocking this pathway could reduce disease risk. This project aims to test whether turning off specific genes in liver cells using a targeted therapy, can decrease lipotoxic levels of these harmful molecules and EVs, and thereby slow down processes linked to atherosclerosis in disease models. You will study how these isolated EVs affect other cells involved in blood vessel health and inflammation. Specifically, you will determine the role of EV-mediated communication to the increased buildup of fatty deposits in blood vessels in functional in vivo and cellular assays. By understanding and blocking this harmful cell-to-cell communication, our research could lead to new treatments for atherosclerosis and related conditions, improving heart and liver health for many people. In addition, you will gain hands-on experience with the industrial collaborator since the proposed project aligns closely with their strategic and commercial objectives by advancing the applications and development of our solutions for EV production, isolation, and sample preparation. Enquiries are encouraged! for further information please contact Dr Nimesh Mody (n.mody@abdn.ac.uk) Candidate Background: Applicants must have obtained, or expect to obtain, a first class UK honours degree or a 2:1 honours degree, or equivalent for degrees obtained outside the UK, in a relevant subject. It would be desireable for the candidate to have experience in cell culture and isolation and characterisation of extracellular vesicles. We welcome applications from those returning from a career break, industry, or other roles, and exceptions can be made where applicants demonstrate excellence through alternative means, including performance in masters courses, professional placements, internships, or employment. We actively encourage applications from diverse career paths and backgrounds and across all sections of the community, regardless of age, disability, ethnicity, gender, gender expression, sexual orientation and transgender status, amongst other protected characteristics. Application Procedure To apply, please submit the following documents via email to smmsn-pgrenquiries@abdn.ac.uk Your application should be a single email with the subject line: “Nimesh Mody MRS – [Your Name]” and include only these documents: A cover letter addressed to the supervisor of the project you are applying for indicating why you are interested in the studentship and what qualities you can bring to the Studentship. An up-to-date CV detailing your academic qualifications, work, and any other relevant experience The names and contact details (including email addresses) of at least two academic referees. Clear copies of your degree certificates and transcripts (if available). Important Notes: No research proposal is required. Please do not include any additional documents (e.g., high school certificates, conference papers/attendance certificates, dissertations). Please note, your application may be shared with the funders of this PhD Studentship, Medical Research Scotland and Vesiculab Ltd. Interviews are expected to take place shortly after the closing date for applications. It is anticipated that the PhD Studentship will start 5 October 2026. Funding Notes This PhD Studentship provides: an annual tax-free stipend of £21,416, increasing to £21,991 over the four years; tuition fees at home UK rates only; consumables; and generous travel allowance. International fees are not covered. International students applying for the Studentship must provide evidence by the date of interview that they are able to finance the fee top-up required to the international fee level. References Aberdeen Cardiovascular & Diabetes Centre https://www.abdn.ac.uk/acdc/Dr. Nimesh Mody https://www.abdn.ac.uk/people/n.modyMahmood, S., (2025) https://doi.org/10.1113/EP092535Oliver, H., (2023) https://doi.org/10.1186/s12967-023-04598-2Thompson, D., (2023) https://doi.org/10.1038/s41598-023-30759-wThompson D, (2017) https://doi.org/10.1042/CS20171066.  

Details We are pleased to offer an exciting opportunity to join a fully funded, four-year IBioIC Industrial PhD Programme. This studentship provides a financial package to support your research, including home tuition fees, a tax-free student stipend, and an allocated consumables budget. The studentship also provides a key industrial placement at Ingenza Ltd in Edinburgh, ideally undertaken during your final year. This project aims to develop a novel chemoenzymatic platform for the site-selective conjugation of antibodies with cyclic peptides via recruiting enzymes that can selectively install reactive chemical handles in peptides and antibodies under mild aqueous conditions, followed by chemoselective coupling to generate well-defined conjugates. Cyclic peptides hold high therapeutic potential as they can modulate challenging disease-relevant protein-protein interactions. Their conjugation with antibodies will significantly improve specificity and reduce toxicity. By combining peptide synthesis, enzyme engineering and bioconjugation chemistry, the project will address key limitations of existing antibody conjugation methods, particularly poor control over modification site and product heterogeneity. The project offers a unique training opportunity for prospective students to gain interdisciplinary, hands-on experience in peptide synthesis, enzymology, recombinant protein expression and purification, bioconjugation chemistry and analytical characterization. The project plan involves an industrial placement for eight months at Ingenza Ltd, providing students with experience of an industrial biotechnology environment. The collaboration with Ingenza Ltd., in this project, will enable the translation of the research into scalable and commercially relevant bioprocesses. Informal enquiries are encouraged, please contact Dr Wael Houssen (w.houssen@abdn.ac.uk) for further information. Candidate Background: Please note a 2.1 at honours level (or UK equivalent) is the standard entry requirement for PhD level study The ideal candidate will have a Bachelor’s degree in Biochemistry, Chemistry, Biotechnology, Pharmaceutical Sciences or relevant fields. Experience and understanding of methods such as chemoenzymatic synthesis and/or protein expression and purification would be an advantage. Promoting equality, diversity, and inclusion is at the heart of the University of Aberdeen. We welcome applicants from all backgrounds and actively encourage applications from people with diverse career paths, regardless of age, disability, ethnicity, gender, sexual orientation, or other protected characteristics. Application Procedure Important note: This project is open only to applicants eligible for the Home/UK fee rate. This includes EU students who hold settled or pre-settled status and meet the relevant residency criteria. To apply, please submit the following documents via email to smmsn-pgrenquiries@abdn.ac.uk A cover letter addressed to the supervisor of the project you’re applying for. An up-to-date CV detailing your academic qualifications, employment history, and any other relevant experience. Please ensure your current permanent address is clearly stated, as this will be used to determine your fee status. Clear copies of your degree certificates and transcripts (if available). Evidence of settled or pre-settled status (if applicable). Two academic references. We cannot request references on your behalf. Please either provide us with copies yourself or have your referees email them directly to us. Direct emails from referees must include your full name and the project you are applying for. Please send your application with documents attached as a single email with the subject line: “IBiolC_WH – [Your Name]” The deadline for applications is 23:59 GMT on 15th July 2026. Please note that incomplete applications will not be considered. For any enquiries regarding your application or the application process, please contact smmsn-pgrenquiries@abdn.ac.uk Funding Notes This IBioIC Industrial PhD Programme is fully funded for 4 years, and the fund covers the student tuition fees (home fees only), student stipend (estimated at £21,383 for the 2026/27 academic year) and a consumable budget. During the PhD, the student may need to relocate to Edinburgh for a placement at Ingenza Ltd. Ideally, during the 4th year of the PhD programme.   The Expected start date is October 2026 References [1] Angew Chem Int Ed (2023) 62, e202215979.[2] Biochem Soc Trans (2025) 53, 1129.[3] ChemBioChem (2023) 24, e202300372. Apply Now

Details We are pleased to offer an exciting opportunity to join a fully funded, 36-month project commencing in October 2026, supported by an Anatomical Society Prize Studentship. This studentship provides a comprehensive financial package to support your research at the University of Aberdeen, including home tuition fees, a tax-free student stipend (estimated at £21,383 for the 2026/27 academic year), and all associated research costs. The studentship also provides funding for attendance at three Society conferences and one overseas meeting to present your data. Spinal muscular atrophy (SMA) is a rare and recessive form of motor neuron disease that predominantly affects the infant population. Defined by progressive motor neuron death, SMA results in skeletal muscle wasting and respiratory failure, and was until the advent of therapy, the most common inherited cause of infant death worldwide. There are now four approved therapies for SMA, all designed specifically to alleviate motor neuron loss, which are improving motor abilities and increasing patient survival. However, widespread tissue and organ pathology beyond the neuromuscular system is now described in multiple animal models and in patient tissues. Much of this work has been carried out in our laboratory (see references). Systemic manifestations of SMA were largely sub-clinical, but they are now much more likely to be revealed as life-span improves following treatment. Chief amongst these are neurodevelopmental and cognitive defects. Our laboratory is particularly interested in the microvascular phenotypes that are present in SMA mouse models and tissue from SMA patients. Recently we have developed a novel mouse model where SMA cellular pathology is driven exclusively in endothelial cells: EndoSMA mouse. This model has a gross and a cellular phenotype, and preliminary data suggests significant developmental defects in specific areas of the brain, including the hippocampus. We hypothesise that the development of the neurovascular niche may be of critical importance in this. This research project will focus on understanding the mechanisms and implications of microvascular pathology in the brain in SMA. This will lead us to potential future combinatorial therapeutic avenues for treated children. You will initially carry out morphological experiments to describe and quantify brain defects in the EndoSMA mouse. You will also use rare post-mortem tissue from SMA patients to validate changes found. You will then investigate the mechanisms that drive these changes. You will also have access to samples from animals and patients treated with current therapies, allowing you to examine the efficacy of these treatments for microvascular pathology. Techniques involved in the research include microdissection, tissue preparation, histology: sectioning, staining, and advanced microscopy, identification and quantification of pathophenotypes in mouse tissues and pathology in patient samples; molecular analysis, data analysis and presentation. The SMA reseach community is active and engaged in improving outcomes for patients. The recent introduction of newborn screening in Scotland, and shortly in England, provides a drive and focus for these efforts. The Parson laboratory has a long tradition of training scientists in morphological investigations, to observe closely, interpret carefully and present in detail the pathology observed in tissues and organ systems. You will be joining a small, but well-connected research laboratory based in the Institute for Medical Sciences at the Foresterhill Healthcare campus of the University of Aberdeen. Contact simon.parson@abdn.ac.uk with any questions and for further information. Candidate Background: An open and enquiring mind and a willingness to develop the skills to work independently. A first degree including morphological or anatomical content such as, but not limited to, zoology, anatomy, neuroscience, biomedical sciences. Completion of a previous research project as well as some experience of histological techniques and wet laboratory research would be useful.  We also invite applications from those returning from a career break, industry or other roles. We typically require a minimum of a 2:1 UK Honours degree (or equivalent), but exceptions can be made where applicants can demonstrate excellence in alternative ways, including, but not limited to, performance in masters courses, professional placements, internships or employment. We actively encourage applications from diverse career paths and backgrounds and across all sections of the community, regardless of age, disability, ethnicity, gender, gender expression, sexual orientation and transgender status, amongst other protected characteristics. Application Procedure A cover letter addressed to the supervisor of the project you’re applying for. An up-to-date CV detailing your academic qualifications, employment history, and any other relevant experience. Please ensure your current permanent address is clearly stated, as this will be used to determine your fee status. Clear copies of your degree certificates and transcripts (if available). Evidence of settled or pre-settled status (if applicable). Two academic references. We cannot request references on your behalf. Please either provide us with copies yourself or have your referees email them directly to us. Direct emails from referees must include your full name and the project you are applying for. Please send your application with documents attached as a single email with the subject line: “Anatomical Society PhD – [Your Name]” The deadline for applications is 23:59 GMT on 12th July 2026. Please note that incomplete applications will not be considered. For any enquiries regarding your application or the application process, please contact smmsn-pgrenquiries@abdn.ac.uk Funding Notes This 36-month project is supported by a prestigious Anatomical Society Prize Studentship. The funding package covers Home tuition fees, research costs, and a tax-free student stipend (estimated at £21,383 for the 2026/27 academic year). The studentship also includes funding to present your research at three Anatomical Society conferences and one overseas meeting. References General SMA background• Mercuri, E., Sumner, C.J., Muntoni, F. et al. Spinal muscular atrophy. Nat Rev Dis Primers 8, 52 (2022).• Yeo CJJ, Darras BT. Yeo and Darras: Extraneuronal Phenotypes of Spinal Muscular Atrophy. Ann Neurol. 2021 Jan;89(1):24-26. doi: 10.1002/ana.25930. Epub 2020 Oct 29.• Yeo CJJ, Tizzano EF, Darras BT. Challenges and opportunities in spinal muscular atrophy therapeutics. Lancet Neurol. 2024 Feb;23(2):205-218. doi: 10.1016/S1474-4422(23)00419-Recent relevant Parson Lab papers• Allardyce H, Lanz H, Lawrence BD, Crawford TO, Sumner CJ, Parson SH. Microvascular pathology in the spinal cord of severe spinal muscular atrophy patients. Acta Neuropathol Commun. 2026 Feb 15;14(1):65. doi: 10.1186/s40478-026-02232-y.• Allardyce H, Lawrence BD, Crawford TO, Sumner CJ, Parson SH. A reassessment of spinal cord pathology in severe infantile

About Acute myeloid leukaemia (AML) is the second most common leukaemia in children and adolescents and the leading cause of childhood leukemic mortality. With the current treatment, based on chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT), 65-75% of patients will achieve long-term survival, however too many children with AML will die from direct complications of the harsh treatment or relapse, whereas the survivors suffer unacceptably high rates of long-term morbidity resulting from chemotherapy exposure or sequelae of bone marrow transplantation. For elderly AML patients, the chances of survival are even worse (13.6%). As a result, identifying new targeted therapy and cell therapy to improve overall survival in these patients remain an unmet clinical need and the goal of Dr Maria Teresa Esposito’s research team. Her team has recently discovered that high level of expression of the gene SET significantly correlate with worse overall survival in adult AML. Strikingly, silencing SET abrogated the clonogenic potential of AML cells carrying various cytogenetic abnormalities and decreased the expression of HOXA genes, which are part of a gene expression signature highly predictive of poor outcomes and relapse in AML. This PhD project will continue this research and will explore the role of SET in haematopoietic and leukemic stem cells, by employing an integrated molecular approach and animal models. The successful applicant will be highly self-motivated, possessing the organizational skills, resilience and drive necessary to manage an independent research project and produce high-quality impactful academic research. The PhD student will be embedded in the sections of Immunology and Oncology and will benefit from the knowledge, experience and the multidisciplinary focus of the supervisory team, including Dr Lisiane Meira, an expert of DNA damage and its impact in cancer and chronic diseases, and external collaborators. Related links School of Biosciences Section of Immunology Section of Oncology Eligibility criteria This studentship is open to candidates who pay UK/home rate fees. Applicants should ideally hold an excellent honours science degree (e.g. First class or international equivalent) and a masters degree in Cancer Biology, Molecular Biology, Biochemistry, Biomedical science or related discipline. Evidence of having undertaken a research project in a prior setting is essential. Knowledge of cancer biology or experience with cell culture, biological assays, cloning, flow cytometry or in vivo work will be an advantage. The successful applicant will be highly self-motivated, possessing the organizational skills, resilience and drive necessary to manage an independent research project and produce high-quality impactful academic research; they must have excellent communication skills with a very high level of written and spoken English. How to apply Applications should be submitted via the Biosciences and Medicine PhD.programme page. In place of a research proposal, you should upload a document stating the title of the project that you wish to apply for and the name of the relevant supervisor. Studentship FAQs Read our studentship FAQs to find out more about applying and funding. Application deadline 12 July 2026 Contact details Maria Teresa Esposito E-mail: mariateresa.esposito@surrey.ac.uk Apply Now